1. Technology is in sync with international standards, ranking among the world's top tier.
Multiple domestically produced CAR-T products have been approved, placing China among the world's leading countries in the number of approved CAR-T products. The technology is on par with Europe and the United States, demonstrating that the R&D capabilities of domestic pharmaceutical companies have reached world-class levels. Significant breakthroughs have been achieved in target development and production processes, and the efficacy and safety have gained international authoritative recognition.
2. A vast amount of clinical experience to handle complex cases.
With a world-leading number of registered clinical studies covering multiple subtypes of hematologic malignancies and exploring a wider range of indications, the hospital boasts a large patient base that provides physicians with extensive practical experience, giving them a significant advantage in managing relapsed or refractory cases, side effect management, and personalized treatment plans.
3. Significant cost advantages, improving treatment accessibility
Compared to the hundreds of thousands of dollars required for treatment in Europe and the United States, the cost of treatment in China is significantly lower, making cutting-edge therapies an affordable clinical option instead of exorbitantly priced drugs. Under the same conditions, the overall cost is usually only one-third of that in Europe and the United States, or even lower.
4. Real-world benefits
It has successfully treated thousands of patients with an excellent objective remission rate, bringing long-term survival hope to patients with relapsed and refractory disease.
Drug approval reforms are accelerating the launch of innovative therapies, allowing patients to benefit from cutting-edge global cell therapy technologies as soon as possible.